SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
13 sept. 2024 07h00 HE
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
09 sept. 2024 07h00 HE
|
SAB Biotherapeutics, Inc.
SAB BIO presents clinical trial progress update at EASD conference
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
04 sept. 2024 07h05 HE
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
08 août 2024 17h51 HE
|
SAB Biotherapeutics, Inc.
FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO...
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
05 août 2024 07h30 HE
|
SAB Biotherapeutics, Inc.
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
SAB BIO Appoints Lucy To as Chief Financial Officer
31 juil. 2024 07h30 HE
|
SAB Biotherapeutics, Inc.
SAB BIO Appoints Lucy To as Chief Financial Officer
SAb Biotherapeutics Rebrands as SAB BIO
20 juin 2024 07h20 HE
|
SAB Biotherapeutics, Inc.
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE...
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
18 juin 2024 13h10 HE
|
SAB Biotherapeutics, Inc.
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a...
SAB Biotherapeutics Announces Departure of Chief Financial Officer
30 mai 2024 16h45 HE
|
SAB Biotherapeutics, Inc.
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
21 mai 2024 07h15 HE
|
SAB Biotherapeutics, Inc.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics